Biotech "Tweets of the Week"
A Thanksgiving Double Helping
(November 23 - December 4, 2015)
Featuring:
$ADRO $AGN $AMGN $BLCM $BLUE $BMRN $DYAX $GILD $GNVC $INSY $KBIO $NWBO $PFE $PRQR $QURE $RLYP $RPRX $SRPT $ZFGN $XBI $IBB #ASH15
Looking for past biotech highlights? Check out the Biotech Tweets of the Week archive.
Pf-Allergan Tie-up Comes to Fruition $PFE $AGN
$PFE and $AGN set for a.m. announcement. 11.3 PFE for each AGN. AGN to own 44% of combined co. Becomes most powerful co. In pharma.
— DAVID FABER (@davidfaber) November 23, 2015
So much for FTC or Treasury, at this point the only thing stopping the merger is the CEOs' sense of decency . . . so in other words: nothing
— David Maizenberg (@biologypartners) November 23, 2015
If deal goes thru # of public co's becoming 1 in last 2 years seems remarkable $DRTX+ $FURX-> $FRX-> $ACT+ $KYTH-> $AGN+ $PFE->?
— j l (@bio_clouseau) November 23, 2015
Pfizer was founded in Brooklyn in 1849. It mass produced penicillin in WWII. It's CEO works in Manhattan. Soon, it will all be...Irish. $PFE
— Dennis K. Berman (@dkberman) November 23, 2015
@ReformedBroker Don't worry. You wouldn't be dating her. She'd be dating you. Totally different.
— Dan Primack (@danprimack) November 23, 2015
@redacre I suspect a lot of cash will be used to buyback shares more than dividends.
— David Sobek (@dsobek) November 23, 2015
@matthewherper Actually approximately 44%. Big company, each point means a lot...
— Brent Saunders (@brentlsaunders) November 23, 2015
WH Spox Josh Earnest on Pfizer/Allergan: "The Treasury Department is rather limited on what they can do admnistratively."
— Eamon Javers (@EamonJavers) November 23, 2015
Biomarin's No Good Very Bad Day at the FDA $BMRN $SRPT
— Bio Stocks™ (@BioStocks) November 24, 2015
If you’re tweeting about $BMRN FDA panel today, pls include #DMD15 hashtag to facilitate searching. You might even end up in my live blog.
— Adam Feuerstein (@adamfeuerstein) November 24, 2015
Well we're counting on you Twitter & @adamfeuerstein for liveblog, looks like the FDA hit stream limit $BMRN $SRPT pic.twitter.com/RQACK1WbHI
— Adam Singer (@AdamSinger) November 24, 2015
FDA stat reviewer: Unlimited post hoc analyses can be run on drisa 6min walk test. None can answer the Q: Does the drug work? Ouch #DMD15
— Luke Timmerman (@ldtimmerman) November 24, 2015
Important slide by FDA on post-hoc analyses of a failed study: not only to $BMRN, but every biotech co and investor pic.twitter.com/xxf0EC1222
— Andy Biotech (@AndyBiotech) November 24, 2015
#FDA - patients in placebo seem to do better than those treated with#Drisapersen #DMD15 $BMRN
— jenn mcnary (@jennmcnary) November 24, 2015
#DMD15: This is brutal
— Jessica Adams (@RxRegA) November 24, 2015
This ADCOM would have been much easier on $BMRN if the FDA was not allowed to present slides.... $SRPT watching pic.twitter.com/QDBD2s6ykZ
— John Hall (@johnhallnj) November 24, 2015
$SRPT down 4% as FDA discusses Drisa's safety profile....wasn't etep safer? $BMRN #DMD15
— Juan P. Serrate, DVM (@JPZaragoza1) November 24, 2015
$BMRN: We couldn't produce dystrophin so it shouldn't be a surrogate. $SRPT
— Greg Wierenga (@Gdubya1) November 24, 2015
FDA still has yet to receive the requested nat history dataset from $BMRN #DMD15
— zach (@zbiotech) November 24, 2015
@dan_smithey no.
— Adam Singer (@AdamSinger) November 24, 2015
@Mykalt45 @zbiotech Don't think anyone expected this level of criticism for $BMRN
— Dan Smithey (@dan_smithey) November 24, 2015
@Pharmdca FDA workshop suggested that no validated Dx available, yet. Will see what FDA review of SRPT Dx finds
— Pierre Bedard (@PRB51) November 24, 2015
@adamfeuerstein Yes. They could. Depends on the panel.
— Matthew Herper (@matthewherper) November 24, 2015
@andybiotech @matthewherper If that is true, and correlates clinically, how does one even think about that? In CF 20% is thought of as good.
— Michael Torres, PhD (@Mykalt45) November 24, 2015
Drisa pt: "The injection site rx don't bother me too much. I used to have bruises and scrapes all over, so what's the difference?" $BMRN
— Meg Tirrell (@megtirrell) November 24, 2015
#DMD15 @matthewherper Frankly doubt $SRPT can satisfy FDA when reviewers are presenting dystrophin data this way -> pic.twitter.com/4rSvgVkzFm
— Andy Biotech (@AndyBiotech) November 24, 2015
#DMD15 $BMRN $SRPT @lisamjarvis DMD pts need 300%+ increase from baseline to get to Becker level of dystrophin exp. pic.twitter.com/GgOQsGPcDI
— Andy Biotech (@AndyBiotech) November 24, 2015
Furlong: "Duchenne has a perfect record of lives claimed." #DMD15 $BMRN $SRPT
— Meg Tirrell (@megtirrell) November 24, 2015
How bad must this disease be if people are begging #FDA to approve a drug that probably doesn't work and may kill them $BMRN $SRPT
— Dan Rosenblum (@sharkbiotech) November 24, 2015
These are seriously the most muddy FDA questions ever. $BMRN #DMD15
— Matthew Herper (@matthewherper) November 24, 2015
$PTCT shares go positive for the day, what a roller coaster $BMRN, $SRPT #DMD15
— Sasha Damouni Ellis (@SashaDamouni) November 24, 2015
#DMD15 Why didn't the FDA just ask a direct question about approval? Geez!
— Jessica Adams (@RxRegA) November 24, 2015
. @AndyBiotech Yes. And deserves to be shot down. Panel could revolt -- they're not interested.
— Matthew Herper (@matthewherper) November 24, 2015
#PCNS panelist: My question is about the question (join the club)
$BMRN #DMD15 #FDA
— Donna Young (@ScripDonnaDC) November 24, 2015
$BMRN seeking approval for new adcom-skipping technology™
— The Skeptic (@TheSkeptic21) November 24, 2015
Results Wire: US FDA AdComm Gives Input on BioMarin’s Drisapersen for Duchenne Muscular Dystrophy #DMD15 $BMRN #DMD https://t.co/EX3SkGwFtu
— SAC Tracker (@FDAadcomm) November 25, 2015
$BMRN Duchenne Drug is Done, $SRPT Survives But Faces Challenge —> https://t.co/Hk9EHFZXSt
— Adam Feuerstein (@adamfeuerstein) November 25, 2015
Two strikes and you're out for Zafgen? $ZFGN
After a Clinical Trial Death, Zafgen Presses On, Families Stay Calm https://t.co/2dUyaUy7ty $ZFGN @PWSAUSA
— Ben Fidler (@BentheFidler) November 23, 2015
$ZFGN James Flynn bought more shares back than he sold in the last 2 Qs as of 11/19, a smart trade, sold high, now bought back low.
— HedgeMind (@HedgeMind) November 30, 2015
$ZFGN Death in OLE PWS study
— j l (@bio_clouseau) December 2, 2015
$ZFGN says another Prader-Willi patient in beloranib extension study died from a blood clot.
— Adam Feuerstein (@adamfeuerstein) December 2, 2015
$ZFGN ↓ 50% PM
— Bio Stocks™ (@BioStocks) December 2, 2015
$ZFGN Obesity Drug Marred by Second Patient Death https://t.co/B97sZvt2H7 via @TheStreet
— Adam Feuerstein (@adamfeuerstein) December 2, 2015
Perhaps the most remarkable element of the Zafgen story was the rally in the stock between 1st patient death and this morning.
— Charley Grant (@CGrantWSJ) December 2, 2015
$ZFGN gave us another trade, awesome
— Nathan Michaud (@InvestorsLive) December 2, 2015
@Mykalt45 I suspect they'd tell you there are always a few blowouts when you aim big. VCs have been doing fine, so they'll take it in stride
— John Carroll (@JohnCFierce) December 2, 2015
Cowen $ZFGN As the risk of DVT and death grows, the level of benefit necessary seems increasingly difficult to achieve.
— dough (@tgtxdough) December 2, 2015
$ZFGN pat who died was cleared to re-enter study after passing co.’s new safety screens. Then died from blood clot, per RBC.
Really bad.
— Adam Feuerstein (@adamfeuerstein) December 2, 2015
@megtirrell @ldtimmerman @LifeSciVC Did you discuss $ZFGN blow up? Good case study for, when seemingly good things go really wrong.
— Adam Feuerstein (@adamfeuerstein) December 3, 2015
$ZFGN Beloranib IND Placed On Complete Clinical Hold
— Bio Stocks™ (@BioStocks) December 3, 2015
@BioDueDiligence sadly enough it might have the best shot of all those
— zach (@zbiotech) December 3, 2015
Newsflash: Gilead sought HCV profits $GILD
Our 18-month investigation into pricing of Sovaldi found Gilead maximized revenue regardless of human consequences. https://t.co/ahcVtSWsbf
— Ron Wyden (@RonWyden) December 1, 2015
$GILD's confidential Sovaldi pricing scenarios (page 30) https://t.co/sGAu5EeIwk pic.twitter.com/OVyA2AqPAD
— Arsalan Arif (@AKAarsalan) December 2, 2015
@RonWyden @eperlste It now costs half as much to treat a pt, takes 1/4 as long, and they're twice as likely to be cured
— John (@JohnTuckerPhD) December 2, 2015
But seriously, it took 20,000 pages of documents and 18 months for Congress to find that $GILD was trying to maximize revenues
— Tyler (@TylerHCanalyst) December 1, 2015
Wyden-Grassley $GILD report seems to express shock that capitalism exists
— Meg Tirrell (@megtirrell) December 1, 2015
Wyden-Grassley rpt is a pretty big waste of taxpayer money. $GILD
— Roy Friedman (@DewDiligence) December 1, 2015
$GILD took a $11B risk with sovaldi before approval. Good to keep things in context. Any unexpected AEs could have derailed it.
— avidresearch (@avidresearch) December 2, 2015
When biotech implodes from its currently over heated state, $GILD will be there buying everything with potential. #timestamp #biotechBRK
— Jacobim Mugatu (@mugatushair) December 3, 2015
Shkreli gets quickly down to business at KaloBios $KBIO
@Drchik23 make that $35
— vlad33301 (@vlad33301) November 23, 2015
This is an understatement....serious homelessness coming to the chat room bros who had the genius idea to short $KBIO
— Chet Stedman (@ChetStedman5) November 26, 2015
Here is @matthewherper's writeup on the $ESRX $IMMY news: https://t.co/ubv8CpmfoK
— Brad Loncar (@bradloncar) December 1, 2015
Exchange between Turing CEO Shkreli and $ESRX CMO Miller at #forbesrx https://t.co/YIWP9LKnd3
— Jonathan Rockoff (@jonathanrockoff) December 3, 2015
$KBIO raises $8.2m for 280,170 share
— Shane Blackmon (@shaneblackmon) December 3, 2015
$ABBV recently paid $350m for a Priority Review Voucher.... 5m shares outstanding in $KBIO. If they get approved for Chagas, it's a homerun
— Shane Blackmon (@shaneblackmon) December 3, 2015
Joke's going to be on us if Shkreli becomes a Randal Kirk of sorts. Chagas move looks timely (been all over the news) and reasonable. $KBIO
— Cody (@codytrades) December 3, 2015
$KBIO Flashbacks to $RTRX in early 2014. Oh my the similarities...
— PropThink (@PropThinker) December 3, 2015
I've said this for a while anti-infectives are due for major price increases - shkreli et al using that investment thesis $kbio
— Dr. Tro Kalayjian (@TroKalayjianCRG) December 3, 2015
$KBIO wants to get an orphan designation for a disease that affects 300,000 Americans? Huh? https://t.co/Ad5m7jCJQz
— Rare Disease Report (@RareDR) December 4, 2015
$KBIO expects to file Benznidazole NDA by YE'16.
— Bio Stocks™ (@BioStocks) December 4, 2015
$KBIO filed a pretty extensive slide deck: https://t.co/Qa1ji4fxKc
— Andrew G. (@BioDueDiligence) December 4, 2015
Seen on the stream...
MS:"Phase1 trial(NCT02140554)on BB305, $BLUE Severe Sickle Cell Disease has delayed primary completion date from January 2018 to March 2019"
— Tom Silver (@TomSilver39) November 23, 2015
$GILD European Commission Grants Marketing Authorization For Single Tablet Regimen Genvoya For The Treatment Of HIV-1 Infection.
— Bio Stocks™ (@BioStocks) November 23, 2015
$AMGN exclusive deal w/CVS for repatha
— zach (@zbiotech) November 23, 2015
(5% pos, may go to 10) $SRPT = game on
— Olddogwithnewtrix (@olddoggnewtrix) November 23, 2015
Translating today’s $CYTR aldoxorubicn GBM PR for you:
Results bad, uninterpretable at best, but we paid group of docs to recommend ph3.
— Adam Feuerstein (@adamfeuerstein) November 23, 2015
$SRPT Closed remaining position here at $36.45 for a nice +49% on the trade. Don't want to risk nice gains thru $BMRN panel volatility $$
— TurboResearch (@TurboResearch) November 23, 2015
Who would've thought competition for CF patients for clinical trials would be a real problem. Mixed blessing?? $VRTX $GLPG $PTCT $PRQR
— Michael Torres, PhD (@Mykalt45) November 23, 2015
Unreal day in turd-biotech land... $AEZS now up 136%
— Shane Blackmon (@shaneblackmon) November 23, 2015
Icydk, $CEMP will soon file for an IND for Sol in ophthalmic diseases (like blepharitis). Yet another expanded use to work into your models
— Phil Kobi (@PhilKobi) November 24, 2015
Storyline worth examining? As details emerge, some redemption for $GSK on $BMRN $FOLD decisions?
— Andrew G. (@BioDueDiligence) November 24, 2015
FDA Opdivo approvals now coming in one every 24 hours. https://t.co/NhI4i30eru
— Brad Loncar (@bradloncar) November 24, 2015
Liberia reporting death of a 15yr old boy from #ebola
— Red Acre Investments (@redacre) November 24, 2015
$AUPH DSMB 3rd pre-planned safety review of patients enrolled in the study and recommended continuation of the trial w/out any modification
— HANK (@BlackHawkTrader) November 24, 2015
10-Q last night from $ADRO reveals a patient developed Listeria. Oppenheimer thinks that the SAE will inevitably raise questions. ain't good
— Marc Lehman (@markflowchatter) November 24, 2015
$ADRO -11% on case of listeriosis disclosed in 10-Q, similar to $ADXS and raising question to these Listeria vaccines. Clinical hold coming?
— Andy Biotech (@AndyBiotech) November 24, 2015
Wow: BGI Halts Revolocity Launch, Cuts @CompleteGenomic Staff as Part of Strategic Shift https://t.co/T16BwjYGGm via @GenomeWeb
— Theral Timpson (@theraltweet) November 24, 2015
@dcamtrades $QURE 50MA is crucial too, 20.20 triggers Volstop Buy also pic.twitter.com/RXyK4T6mjg
— SwoleStreet (@yoldash718) November 24, 2015
Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC for EU Health Fund https://t.co/voRy3yEjgY pic.twitter.com/umLhA4NxM1
— Labiotech.eu (@Labiotech_eu) November 24, 2015
$ADRO: all clinical trials continue unchanged. FDA fully aware. $ADXS
— Jacob Plieth (@JacobPlieth) November 25, 2015
$ADRO is allowing a lot of Q&A, which is a good sign.
— Roy Friedman (@DewDiligence) November 25, 2015
For better or worse, $ADRO is physically laughing when he describes why they didn't disclose this prior to the Q.
— Brad Loncar (@bradloncar) November 25, 2015
$XBI triggered. Let's see if we can get a run into the end of 2015.
— BioBounce.com (@BioBounce) November 25, 2015
The past month or so for me $RLYP up 100% $FOLD up 80% $ZFGN up 75% □
— Kaushik (@skaushi) November 25, 2015
"Price increases have been off the charts. None of this makes any sense other than that they can get away with it.” https://t.co/8amBBwucTV
— Dr. Tro Kalayjian (@TroKalayjianCRG) November 26, 2015
My portfolio going into end of year: $srpt $qure $rlyp (big positions) $onty $espr $neot $cbay $gpro (avg 19.2) few $fit $adap
— PHARMD (@Pharmdca) November 26, 2015
CRL for 1 indication & sBLA acceptance for another w/ Jan 23, 2016 priority review. #melanoma $bmy
— Joe (@Drchik23) November 27, 2015
Highly recommend these podcasts if you want some detail on immunotherapy https://t.co/FtY6gKRnfD
— Dan Smithey (@dan_smithey) November 28, 2015
I’m no longer the only person asking questions about $NWBO, apparently.
— Adam Feuerstein (@adamfeuerstein) November 29, 2015
Pretty amazing that woodford didn't read the 10k's and q's
— NathanAaron (@NathanAhron) November 25, 2015
$QURE EU glybera sales started Q3, not pursuing US glybera approval (this is good) data from 2 HemB pts during JPM full cohort prob. EHA
— Red Acre Investments (@redacre) November 30, 2015
$QURE CC takeaways. 1) CBO resigned - instrumental in bldg manu capa 2) hemophilia B interim just before JPM16 3) Next SF data 30 mth EP.
— Beck (@princetongb) November 30, 2015
$RHHBY $500M mistake - to discontinue devel of antibiotic for severe Pseudomonas aeruginosa. Asset ret 2 Polyphor. https://t.co/jXfWyp7EdV
— Beck (@princetongb) November 29, 2015
$SRPT 37 out of 39 locations recruiting patients for the Confirmatory Study of Eteplirsen in DMD Patients (PROMOVI) https://t.co/2f4IylUvVs
— Joe (@GantosJ) November 30, 2015
$RLYP this stock is now become twitter lover stock and pump force, remind me of $BLUE
— $$$ Money $$$ (@BiotechMoney18) November 30, 2015
Kudos to $JUNO for webcasting their #ASH15 analyst event. Will be Dec 7th at 8:30 pm. https://t.co/AhR8AwK1Lq
— Brad Loncar (@bradloncar) November 30, 2015
@AdamSinger I like Uniqure but think CHF is a very hard nut to crack. Interesting biology though.
— Ethan Weiss (@ethanjweiss) December 1, 2015
@JFinDallas @bradloncar @ColfaxCapital May not go away, but not a snowballs chance in hell that any real changes will occur.
— Dan Smithey (@dan_smithey) December 1, 2015
More and more deals are being done early (preclinical) - Reginald Seeto, @MedImmune #biotech #partnering #licensing
— Devin T. Rosenthal (@dtrosenthal) December 1, 2015
$RLYP forming a classic inverted Berens pattern. i.e. go up really fast ^^
— SharpMango (@SharpMango) December 1, 2015
$RPRX Repros Therapeutics Receives CRL From FDA for Enclomiphene
— BioBreakout (@BioBreakout) December 1, 2015
Sold all 50 $RPRX put contracts at 0.71 for #zzporte profit of $2550, now wondering why I didn't hit this harder @portefeuillefun
— Tony Friedman (@zzlangerhans) December 1, 2015
$IBB struggling to sustain any rally, and since life science is where so much of the real growth/innovation is, can't be a good overall sign
— David Maizenberg (@biologypartners) December 1, 2015
Cardinal rule- always have a second program ongoing. Too many companies forgetting to do that lately
— NathanAaron (@NathanAhron) December 2, 2015
Trial is due to read in December. $NBIX
— Alfredo Fontanini (@AF_biotech) December 2, 2015
$DYAX got early HSR termination 4 days after that idiotic short report came out I pray they are still short
— Dan Rosenblum (@sharkbiotech) December 2, 2015
Investors flocking to Medtech in the wake of drug pricing scrutiny. Good piece by @LKrauskopf https://t.co/UPBU4QmmCK
— Daphne Zohar (@daphnezohar) December 3, 2015
$INSY Murder Incorporated: Insys Therapeutics, Part I
https://t.co/2BTO3uQ1hO
— SIRF (@SIRF_Report) December 3, 2015
Honestly even if I wasn't completely bearish #Biotech2015 already, if u showed me $BIIB $GILD chart without labels I'd be "Wow, looks awful"
— Jean Fonteneau (@JFinDallas) December 3, 2015
$insy beatdown from sirf; possible terrorism; $rlyp BS survey; vrx court order; #fifa 92 count indictment; USD. When's the rate hike?#enough
— Joe (@Drchik23) December 3, 2015
Ugly day in biotech. Lets hope no one lays an egg at ASH.
— PropThink (@PropThinker) December 3, 2015
What kind of investor invests in an outfit where the CEO may end up doing jail time for violations of securities law?
— Roy Friedman (@DewDiligence) December 3, 2015
My blog post on $BLCM: “The Bellicum Story: What you Need to Know Going Into ASH 2015” https://t.co/U3xIcWlMBW
— Timothy Sullivan (@tsullivan70) December 3, 2015
@SashaDamouni @RobertLangreth @CynthiaLKoons OMG... only weeks to #JPM16
— Meg Tirrell (@megtirrell) December 3, 2015
@megtirrell @DShaywitz @ldtimmerman we are perilously close to peak CRISPR.
— Michael Gilman (@michael_gilman) December 3, 2015
@bradloncar @AmericanCentury And Genvec $GNVC is partnered up well w/ Novartis $NVS on that gene therapy treatment for hearing
— Me Likeitalot (@Melikeitalot) December 3, 2015
Was holding cash waiting for an opportunity like today. Could continue into next week/Fed.
Biggest buys: $FB, $CELG.
Smaller: $BMY, $RLYP
— HumbleBioTrader (@HumbleBioTrader) December 4, 2015
Latest BofA survey of physicians indicates similar % will prescribe Veltassa as they will ZS9 $RLYP $ZSPH $AZN Edema a concern for 67%
— j l (@bio_clouseau) December 4, 2015
Cowen $OPHT Clinician Consultants Indicate Probability Of Success Of Ongoing Phase III Program Is 60-70%. Target 80
— dough (@tgtxdough) December 4, 2015
$GALE Settles Stock Promotion And Insider Trading Lawsuits. https://t.co/1Vi4sFTuc2
— Bio Stocks™ (@BioStocks) December 4, 2015
$INSY 26.06
Insys Therapeutics Responds to False and Misleading Report
https://t.co/gcTgFmjqNj
— Tom Wrigley (@WrigleyTom) December 4, 2015
$INSY stressing that the FDA hasn't raised concerns re subsys label or requested changes is a nice dodge to issues raised by @SIRF_Report
— zach (@zbiotech) December 4, 2015
RBC floats idea on $INSY goin pvt given all the negative headlines, monster short interest, etc
— zach (@zbiotech) December 4, 2015
$AMGN and $MRK are going to do a Blincyto/Keytruda combo study in DLBCL. Also will test AMG820 (CSF1R) w/ Keytruda. https://t.co/PSl4L6uMc7
— Brad Loncar (@bradloncar) December 4, 2015
Heading down for my annual paparazzi tour of famous heme oncs #ASH15
Hotline bling me for any biotweetups
— Jonathan (@McEuen) December 4, 2015
Big weekend of ASH data, followed by Tues evening data from $ONTY. Finally, some catalysts/data to trade off of.
— Shane Blackmon (@shaneblackmon) December 4, 2015
Piper today $BLCM benefit from high enthusiasm about haplo-identical HSCT. We reiterate PT of $45 as BLCM is one of our top small cap picks.
— dough (@tgtxdough) December 4, 2015
$RLYP vs. $ZSPH -- BAML hyperkalemia survey results
Not surprisingly, advantage to Veltassa in the chronic setting pic.twitter.com/rsFwJam78K
— Andy Biotech (@AndyBiotech) December 4, 2015
Lilly pulls the plug on a massive insulin project in a blow to its diabetes pipeline. https://t.co/4bEQgaM7hF by @DamianFierce $LLY
— FierceBiotech (@FierceBiotech) December 4, 2015
I don't know if it's the perspective of #ASH15 but biotech being sold here again, $BLUE with a casual $4 quick slide... $XBI -1%
— Jean Fonteneau (@JFinDallas) December 4, 2015
Big immuno-oncology deals 2014-2015 $PFE $CLLS $MRK $FPRX $BMY $JUNO $REGN $CELG $NLNK $SAN $ROG pic.twitter.com/rAI0iH1O9J
— Juan P. Serrate, DVM (@JPZaragoza1) December 4, 2015
No mistaking the subject of this conference #ASH15 pic.twitter.com/P7eGV9fkl2
— David Miller (@AlpineBV_Miller) December 4, 2015